To compare the clinical performance of several TSH-R-Ab assays in patients with autoimmune thyroid disease and healthy controls, focusing on sensitivity and specificity.
Key Findings:
All 42 patients without autoimmune thyroid disease tested negative for TSH-R-Ab.
In 104 patients with Graves’ disease, TSH-R-Ab positivity was 63% for Cobas, 65% for Immulite, and 84% for TSI bioassay (p < .0025 for TSI vs Immulite, p < .0009 for TSI vs Cobas).
Newly diagnosed Graves’ disease patients were all positive in the TSI bioassay, while only 73% were positive in Cobas and Immulite.
Binding assays were less sensitive than TSI bioassays and not specific for stimulating antibodies.
Interpretation:
The study demonstrates that bioassays for TSH-R-Ab provide more accurate functional assessments compared to binding assays, which may significantly influence clinical decision-making in the management of autoimmune thyroid disorders.
Limitations:
The study was limited to a specific patient population and may not be generalizable to all demographics.
Only a limited number of assays were compared, which may not represent the full spectrum of available tests.
Conclusion:
Measuring TSH-R-Ab functionality via bioassays can enhance clinical utility in managing autoimmune thyroid diseases, underscoring the importance of appropriate assay selection for optimal patient care.
